the BIRDIE trial
Key facts
- Where
- Rotterdam, HollandiaSee the site
- Phase
- 3. fázis
Where in Hollandia
- Sint Franciscus Vlietland Groep StichtingRotterdam, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sint Franciscus Vlietland Groep Stichting
- Trial code
- EU 2023-505839-12-01
- Record updated
- 2025. december 3.
- Original description
1. To evaluate if it is possible to extend the dosing interval of mepolizumab, driven by eosinophil levels as biomarker in patients with severe eosinophilic asthma without loss of asthma control 2. To evaluate if it is possible to extend the dosing interval of dupilumab, driven by FeNO as biomarker in patients with severe T2-high asthma without loss of asthma controlRead full original descriptionShow less
BIomarker-dRiven Dosing Interval Extension of biologics in asthma (the BIRDIE trial)
1. To evaluate if it is possible to extend the dosing interval of mepolizumab, driven by eosinophil levels as biomarker in patients with severe eosinophilic asthma without loss of asthma control 2. To evaluate if it is possible to extend the dosing interval of dupilumab, driven by FeNO as biomarker in patients with severe T2-high asthma without loss of asthma control
Inclusion: Severe asthma as primary indication for treatment with mepolizumab (one dose every 4 weeks) or dupilumab (one dose every 2 weeks) for the last 6 months; Stable asthma (an ACQ <1.5 and no severe asthma exacerbations) for at least 6 months; Sufficient understanding of the Dutch language.
Exclusion: Treatment with maintenance OCS, defined as treatment with OCS during 14 or more subsequent days, in the last 6 months; Treatment with immunosuppressants (other than mepolizumab, dupilumab or corticosteroids) in the last 6 months; Treatment with, or switching between, other biologics than the drug of interest in the 6 months before inclusion; Pulmonary disease(s) other than asthma (including EGPA); Pregnancy.